IV Iron Treatment Improves Survival in Anemic Patients with Acute Bacterial Infections, Large-Scale Study Shows
核心洞察
A retrospective analysis of over 85,000 anemic patients with acute bacterial infections (搜索) found that intravenous iron treatment significantly reduced mortality at 14 and 90 days across multiple infection types.
The study challenges decades-old medical beliefs that iron infusions worsen bacterial infections, showing instead that IV iron improved survival rates for MRSA bacteremia (搜索), pneumonia (搜索), UTIs, cellulitis (搜索), and colitis (搜索) patients.
Patients receiving IV iron also demonstrated significantly improved hemoglobin levels 60-90 days after treatment compared to those who did not receive iron therapy.
Intravenous iron treatment significantly improves survival and increases hemoglobin levels in anemic patients hospitalized with acute bacterial infections (搜索), according to groundbreaking research presented at the 67th American Society of Hematology (搜索) Annual Meeting and Exposition. The findings challenge decades-old medical beliefs that iron infusions feed bacteria and worsen patient outcomes.
Dr. Haris Sohail, a hematology-oncology fellow at Charleston Area Medical Center (搜索) Institute for Academic Medicine, led the largest study to date examining this controversial clinical question. The retrospective cohort analysis evaluated outcomes in more than 85,000 anemic patients hospitalized with bacterial infections between 2000 and 2024.
Substantial Mortality Reductions Across Multiple Infections
The study demonstrated significant survival benefits across five of six infection types examined. Among 15,022 patients with MRSA bacteremia (搜索), those receiving IV iron showed a 54% reduction in 14-day mortality risk (HR = 0.46; 95% CI, 0.41-0.51) and a 32% reduction in 90-day mortality risk (HR = 0.68; 95% CI, 0.64-0.73).
Similar mortality improvements were observed in pneumonia (搜索) patients, with IV iron reducing 14-day mortality risk by 54% (HR = 0.46; 95% CI, 0.43-0.5) and 90-day mortality risk by 33% (HR = 0.67; 95% CI, 0.65-0.7) among 27,062 individuals analyzed.
For urinary tract infections (搜索), cellulitis (搜索), and colitis (搜索), IV iron consistently reduced both short-term and long-term mortality risks. The only exception was bacterial meningitis (搜索), where 143 patients showed no statistically significant differences, potentially due to the small sample size and severity of the infection.
Challenging Long-Standing Clinical Beliefs
The research directly contradicts widespread clinical practice based on theoretical concerns about iron feeding bacterial growth. "Due to this belief, a lot of patients have been left untreated, probably at a time when the body needed IV iron the most," Sohail explained during his presentation.
Iron deficiency anemia (搜索) affects several million people worldwide and is particularly common in patients who develop acute bacterial infections (搜索). The condition impairs the body's ability to fight infections due to reduced hemoglobin levels, which are essential for oxygen transport and immune function.
"There has always been a concern that if you give IV iron to these patients who have active infection, the iron might feed the bacteria and it might make the infection worse," Sohail noted. These concerns stemmed from laboratory studies showing enhanced bacterial growth in iron-rich environments and conflicting meta-analyses suggesting increased infection risk.
Improved Hemoglobin Recovery
Beyond survival benefits, the study documented significant improvements in hemoglobin levels among patients receiving IV iron. At 60-90 days post-treatment, hemoglobin increases ranged from 1.5-1.6 g/dL in the IV iron groups compared to 0.97-1.1 g/dL in control groups across different infection types.
"With acute infection, the body raises hepcidin, a hormone that traps iron inside immune cells," Sohail explained. "This prevents iron from reaching the bone marrow, making it harder to make red blood cells."
Clinical Practice Implications
The findings have immediate implications for multiple medical specialties. "The clinical implications are massive, not just for the field of hematology, but also for infectious disease, hospital medicine and even critical care medicine," Sohail emphasized.
Currently, many clinicians delay iron treatment until infections resolve, which can take months due to scheduling, insurance issues, or extended hospital stays requiring rehabilitation. This practice may inadvertently harm patients, as iron deficiency compromises immune pathways essential for bacterial clearance.
"Any patient — young, old — if they're iron deficient, they are immunodeficient," Sohail stated. "There are certain immune pathways in your body that need iron to properly function and fight bacteria."
Future Research Directions
The research team is planning randomized prospective trials to confirm these retrospective findings. Future studies will evaluate optimal dosing strategies, timing of administration, iron formulation types, and detailed adverse event profiles.
"I just wanted to see that there would not be any worse mortality if you gave them iron," Sohail said. "If I had gotten that, I would count that as a win, but seeing that the patients who did get iron had better survival, that really caught me off guard."
The study represents the first large-scale analysis to definitively address this long-standing clinical controversy, potentially transforming treatment approaches for the estimated 2 billion people worldwide affected by iron deficiency.